
|Articles|January 1, 2004
Combination kills cancer
New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















